Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biomarkers for Clinical Hypoxia Evaluation in Cervical Cancer
Sponsor: University of Manchester
Summary
Patients with locally advanced cervical cancer (LACC) are primarily treated with radiotherapy +/- chemotherapy however 5-year survival rates are \<60% with significant treatment toxicity. Hypoxia is a well-known radioresistant component of solid tumours such as cervical cancer and hypoxia modification therapies have demonstrated immense promise in treating such tumours. A major factor in determining a successful outcome with hypoxia modification is appropriate patient selection as it is hypoxic tumours that receive the most benefit from hypoxia modifying therapies. To date there is no validated hypoxia biomarker to stratify patients for therapy in cervical cancer in clinical use. This project offers a unique opportunity to examine both genetic and imaging biomarkers to optimise patient stratification when receiving curative radiotherapy for cervical cancer.
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2020-12-10
Completion Date
2027-10-31
Last Updated
2025-01-20
Healthy Volunteers
Yes
Conditions
Interventions
Biopsy of tumour
Cervical tumour biopsy during treatment. This will be used for gene expression (RNA) analysis against a hypoxia associated gene signature.
MRI scans
Multiple magnetic resonance imaging (MRI) scans before and during treatment using oxygen enhanced (OE) / tissues oxygen level dependent (TOLD) sequence
Locations (1)
The Christie NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom